PharVision Advisers’s ResMed RMD Stock Holding History

PharVision Advisers’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,198	Closed	-$289K	–	533
2025 Q4	$289K	Buy	+1,198	New	+$306K	0.15%	291
2025 Q2	–	Sell	-979	Closed	-$219K	–	404
2025 Q1	$219K	Buy	+979	New	+$229K	0.3%	170

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

PharVision Advisers's RMD Position: Q1 2026 in Review

PharVision Advisers sold out of ResMed (RMD) in Q1 2026, closing a stake of 1,198 shares — an estimated $289K sold.

PharVision Advisers first reported a position in RMD in Q1 2025 and held it in 2 quarters. The position peaked at $289K in Q4 2025. 941 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

PharVision Advisers reported no remaining ResMed position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,198 ResMed shares in Q1 2026, an estimated $289K.
PharVision Advisers first reported a position in ResMed in Q1 2025 and held it in 2 quarters.
PharVision Advisers's ResMed position peaked at $289K in Q4 2025.
941 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.